Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Invited Commentary.

Nehs MA.

J Am Coll Surg. 2018 Jun;226(6):959-960. doi: 10.1016/j.jamcollsurg.2018.03.008. No abstract available.

PMID:
29803254
2.

Quantitative Analysis of the Benefits and Risk of Thyroid Nodule Evaluation in Patients ≥70 Years Old.

Wang Z, Vyas CM, Van Benschoten O, Nehs MA, Moore FD Jr, Marqusee E, Krane JF, Kim MI, Heller HT, Gawande AA, Frates MC, Doubilet PM, Doherty GM, Cho NL, Cibas ES, Benson CB, Barletta JA, Zavacki AM, Larsen PR, Alexander EK, Angell TE.

Thyroid. 2018 Apr;28(4):465-471. doi: 10.1089/thy.2017.0655. Epub 2018 Apr 2.

PMID:
29608439
3.

Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule.

Angell TE, Vyas CM, Barletta JA, Cibas ES, Cho NL, Doherty GM, Gawande AA, Howitt BE, Krane JF, Marqusee E, Strickland KC, Alexander EK, Moore FD Jr, Nehs MA.

Ann Surg Oncol. 2018 May;25(5):1410-1417. doi: 10.1245/s10434-018-6421-x. Epub 2018 Mar 8.

PMID:
29520656
4.

4D-CT is Superior to Ultrasound and Sestamibi for Localizing Recurrent Parathyroid Disease.

Hamidi M, Sullivan M, Hunter G, Hamberg L, Cho NL, Gawande AA, Doherty GM, Moore FD Jr, Nehs MA.

Ann Surg Oncol. 2018 May;25(5):1403-1409. doi: 10.1245/s10434-018-6367-z. Epub 2018 Feb 26.

PMID:
29484563
5.

Molecular Testing of Nodules with a Suspicious or Malignant Cytologic Diagnosis in the Setting of Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP).

Strickland KC, Eszlinger M, Paschke R, Angell TE, Alexander EK, Marqusee E, Nehs MA, Jo VY, Lowe A, Vivero M, Hollowell M, Qian X, Wieczorek T, French CA, Teot LA, Cibas ES, Lindeman NI, Krane JF, Barletta JA.

Endocr Pathol. 2018 Mar;29(1):68-74. doi: 10.1007/s12022-018-9515-x.

PMID:
29396809
6.

Differential Growth Rates of Benign vs. Malignant Thyroid Nodules.

Angell TE, Vyas CM, Medici M, Wang Z, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Heller HT, Kim MI, Krane JF, Marqusee E, Moore FD Jr, Nehs MA, Zavacki AM, Larsen PR, Alexander EK.

J Clin Endocrinol Metab. 2017 Dec 1;102(12):4642-4647. doi: 10.1210/jc.2017-01832.

PMID:
29040691
7.

A modified reporting approach for thyroid FNA in the NIFTP era: A 1-year institutional experience.

Mito JK, Alexander EK, Angell TE, Barletta JA, Nehs MA, Cibas ES, Krane JF.

Cancer Cytopathol. 2017 Nov;125(11):854-864. doi: 10.1002/cncy.21907. Epub 2017 Sep 13.

PMID:
28902465
8.

The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas.

Wong KS, Strickland KC, Angell TE, Nehs MA, Alexander EK, Cibas ES, Krane JF, Howitt BE, Barletta JA.

Endocr Pathol. 2017 Jun;28(2):171-176. doi: 10.1007/s12022-017-9476-5.

PMID:
28271380
9.

Prevalence of Contralateral Tumors in Patients with Follicular Variant of Papillary Thyroid Cancer.

Sullivan MC, Graham PH, Alexander EK, Ruan DT, Nehs MA, Gawande AA, Moore FD Jr, Howitt BE, Strickland KC, Krane JF, Barletta JA, Cho NL.

J Am Coll Surg. 2017 Jun;224(6):1021-1027. doi: 10.1016/j.jamcollsurg.2016.12.007. Epub 2016 Dec 23.

PMID:
28017809
10.

Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer.

Gibson WJ, Ruan DT, Paulson VA, Barletta JA, Hanna GJ, Kraft S, Calles A, Nehs MA, Moore FD Jr, Taylor-Weiner A, Wala JA, Zack TI, Lee TC, Fennessy FM, Alexander EK, Thomas T, Janne PA, Garraway LA, Carter SL, Beroukhim R, Lorch JH, Van Allen EM.

Clin Cancer Res. 2017 May 1;23(9):2367-2373. doi: 10.1158/1078-0432.CCR-16-2154-T. Epub 2016 Oct 17.

11.

Identification of Novel Oncogenic Mutations in Thyroid Cancer.

Pitt SC, Hernandez RA, Nehs MA, Gawande AA, Moore FD Jr, Ruan DT, Cho NL.

J Am Coll Surg. 2016 Jun;222(6):1036-1043.e2. doi: 10.1016/j.jamcollsurg.2015.12.047. Epub 2016 Jan 14.

PMID:
27010584
12.

Bethesda Categorization of Thyroid Nodule Cytology and Prediction of Thyroid Cancer Type and Prognosis.

Liu X, Medici M, Kwong N, Angell TE, Marqusee E, Kim MI, Larsen PR, Cho NL, Nehs MA, Ruan DT, Gawande A, Moore F Jr, Barletta J, Krane JF, Cibas ES, Yang T, Alexander EK.

Thyroid. 2016 Feb;26(2):256-61. doi: 10.1089/thy.2015.0376. Epub 2015 Dec 16.

13.

Bilateral neck exploration decreases operative time compared to minimally invasive parathyroidectomy in patients with discordant imaging.

Nehs MA, Ruan DT, Gawande AA, Moore FD Jr, Cho NL.

World J Surg. 2013 Jul;37(7):1614-7. doi: 10.1007/s00268-013-2007-8.

PMID:
23519294
14.

Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.

Nehs MA, Nucera C, Nagarkatti SS, Sadow PM, Morales-Garcia D, Hodin RA, Parangi S.

Endocrinology. 2012 Feb;153(2):985-94. doi: 10.1210/en.2011-1519. Epub 2011 Dec 27.

15.

Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity.

Lin CI, Barletta JA, Nehs MA, Morris ZS, Donner DB, Whang EE, Jeong JW, Kimura S, Moore FD Jr, Ruan DT.

Surgery. 2011 Dec;150(6):1295-302. doi: 10.1016/j.surg.2011.09.014.

16.

Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical cancers.

Nehs MA, Lin CI, Kozono DE, Whang EE, Cho NL, Zhu K, Moalem J, Moore FD Jr, Ruan DT.

Surgery. 2011 Dec;150(6):1032-9. doi: 10.1016/j.surg.2011.09.012.

PMID:
22136818
17.

Minimally invasive adrenal surgery: an update.

Nehs MA, Ruan DT.

Curr Opin Endocrinol Diabetes Obes. 2011 Jun;18(3):193-7. doi: 10.1097/MED.0b013e32834693bf. Review.

PMID:
21494137
18.

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.

Nucera C, Nehs MA, Nagarkatti SS, Sadow PM, Mekel M, Fischer AH, Lin PS, Bollag GE, Lawler J, Hodin RA, Parangi S.

Oncologist. 2011;16(3):296-309. doi: 10.1634/theoncologist.2010-0317. Epub 2011 Feb 25.

19.

Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer.

Nehs MA, Nagarkatti S, Nucera C, Hodin RA, Parangi S.

Surgery. 2010 Dec;148(6):1154-62; discussion 1162. doi: 10.1016/j.surg.2010.09.001.

20.

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression.

Nucera C, Porrello A, Antonello ZA, Mekel M, Nehs MA, Giordano TJ, Gerald D, Benjamin LE, Priolo C, Puxeddu E, Finn S, Jarzab B, Hodin RA, Pontecorvi A, Nose V, Lawler J, Parangi S.

Proc Natl Acad Sci U S A. 2010 Jun 8;107(23):10649-54. doi: 10.1073/pnas.1004934107. Epub 2010 May 24.

21.

Surgical drains can be safely avoided in lateral neck dissections for papillary thyroid cancer.

Mekel M, Stephen AE, Gaz RD, Randolph GW, Richer S, Perry ZH, Lubitz CC, Nehs MA, Parangi S, Hodin RA.

Am J Surg. 2010 Apr;199(4):485-90. doi: 10.1016/j.amjsurg.2009.04.006.

PMID:
20359568
22.
23.

A novel orthotopic mouse model of human anaplastic thyroid carcinoma.

Nucera C, Nehs MA, Mekel M, Zhang X, Hodin R, Lawler J, Nose V, Parangi S.

Thyroid. 2009 Oct;19(10):1077-84. doi: 10.1089/thy.2009.0055.

24.

Immunologic response to cryoablation of breast cancer.

Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JL, Chang AE.

Breast Cancer Res Treat. 2005 Mar;90(1):97-104.

25.

Immunologic approaches to breast cancer treatment.

Sabel MS, Nehs MA.

Surg Oncol Clin N Am. 2005 Jan;14(1):1-31, v. Review.

PMID:
15541997

Supplemental Content

Support Center